Subscribe
Logo small
Search

AOTMiT: The Transparency Council will address allergies, prostate cancer and leukemia, among others

MedExpress Team

Medexpress

Published Aug. 1, 2025 07:06

On Monday, August 4, the next meeting of the Transparency Council.
AOTMiT: The Transparency Council will address allergies, prostate cancer and leukemia, among others - Header image

The agenda includes:

  1. Preparation of a position paper on the evaluation of the drug Staloral 300 (mixtures of allergen extracts)
    Indication: allergic disorders (type I allergy according to the Gell and Coombs classification), caused by pollen allergens, manifested by rhinitis, conjunctivitis, rhinoconjunctivitis or asthma (mild to moderate) in children and adolescents from completed 5 years of age to completed 18 years of age.
  2. Preparation of a position paper on the evaluation of the drug Oralair 100 IR & 300 IR (grass pollen allergen extract)
    Indication: treatment of children (5 years of age and older), adolescents and adults (up to 65 years of age) with allergic rhinitis with or without conjunctivitis, confirmed on the basis of clinical symptoms and a positive spot skin test result and/or the presence of specific serum IgE directed against the pollen of one of the grasses of the panicle group (Pooideae).
  3. Preparation of a position paper on the evaluation of the drug Pluvicto (lutetii (177Lu) vipivotidi tetraxetanum)
    Indication: under drug program B.56 "Treatment of patients with prostate cancer (ICD-10: C61)".
  4. Preparation of an opinion on the active substance arsenicum trioxidum
    Indication: C.65.b. (C92.4) - acute promyelocytic leukemia in patients younger than 18 years of age with a t(15;17) translocation and/or the presence of the PML/RAR-alpha gene.
  5. Preparation of an opinion on the active substance mycophenolas mofetil
    Indications:
    - autoimmune diseases in patients with immune deficiencies,
    - cytopenias in the course of autoimmune lymphoproliferative syndrome.
  6. Preparation of an opinion on the active substance sirolimusum
    Indication: cytopenias in the course of autoimmune lymphoproliferative syndrome - resistant to steroids or with too severe side effects of chronic high-dose steroid therapy.
  7. Preparation of an opinion on the draft health policy program of the local government unit
    Title: "Health policy program in the field of rehabilitation, physical therapy and physiotherapy for residents of the Municipality of Kodrąb for 2025-2027".

Source: AOTMiT

Szukaj nowych pracowników

Dodaj ogłoszenie o pracę za darmo

Lub znajdź wyjątkowe miejsce pracy!

Read also